Tralokinumab

N/A

Report date: 2026/03/16 20:01:47

Base Information

Drug NameTralokinumab
Drug Alias NameAnti-IL-13 monoclonal antibody曲洛吉努单抗Anti-interleukin-13 monoclonal antibodyTralokinumabumtralokinumab-Idrm +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitors
TargetsInterleukin-13
Therapy Area/IndicationsEczemaDermatitis, AtopicIdiopathic Pulmonary Fibrosis +[5] 
Global Approved IndicationsDermatitis, Atopic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/06/17
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesLeo Pharma Asia Pte LtdMedimmune LtdLeo Pharma Inc +[5] 
Inactive CompaniesUniversity of ZurichAstrazeneca PlcMedimmune Llc
Active IndicationsEczemaDermatitis, Atopic
Inactive IndicationsIdiopathic Pulmonary FibrosisAsthmaColitis, Ulcerative

Other Information

ATC CodeD11AH
Related LinksWikipediaDrugBankKEGG